Analyst firms · Needham · RMD
Needham RMD price target and rating history
ResMed Inc. (RMD) · Health Care
Needham rates ResMed Inc. (RMD) Hold with a $180 price target, as of its latest action on Sep 4, 2024. It has published 3 rating actions on RMD since August 2021, including 1 upgrade and 2 downgrades. Across 5 firms with a RMD price target in the last 12 months, the median target is $235.
- Current rating
- Hold
- Price target
- $180
- Median target, all firms
- $235
- Actions on RMD
- 3
Every Needham rating on RMD
- Sep 4, 2024DowngradeNeedham downgrades to Hold from Buy
- Sep 6, 2023
- Aug 2, 2021DowngradeNeedham downgrades to Hold from Buy
How other firms rate RMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | Nov 2, 2026 | |
| RBC Capital Markets | Outperform | $262 | Sep 15, 2026 |
| Rothschild & Co Redburn | Neutral | $230 | Aug 19, 2026 |
| Citigroup | Neutral | $235 | Jul 13, 2026 |
| Morgan Stanley | Equal-Weight | $230 | Jun 17, 2026 |
| Robert W. Baird | Neutral | $275 | Dec 16, 2025 |
Questions about Needham and RMD
- What is Needham's price target for RMD?
- Needham's latest stated price target for ResMed Inc. (RMD) is $180, from its action on Sep 6, 2023.
- What is Needham's rating on RMD?
- Needham rates RMD Hold, a neutral rating, as of Sep 4, 2024.
- When did Needham last change its view on RMD?
- On Sep 4, 2024, Needham downgrades to Hold from Buy.
- How does Needham's RMD target compare with other analysts?
- Across 5 firms with a RMD price target in the last 12 months, the median target is $235.
More RMD rating histories
- RBC Capital Markets13
- Citigroup8
- Morgan Stanley4
- Robert W. Baird4
- CLSA5
- Wolfe Research3
- J.P. Morgan6
- BofA Securities3
All Needham ratingsRMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.